Analysts Set CervoMed Inc. (NASDAQ:CRVO) Target Price at $23.60

CervoMed Inc. (NASDAQ:CRVO) has received an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $23.00.

CRVO has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of CervoMed in a report on Thursday, December 18th. Chardan Capital upped their price objective on CervoMed from $15.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CervoMed in a research note on Wednesday, January 21st. Zacks Research upgraded CervoMed from a “strong sell” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Cantor Fitzgerald began coverage on CervoMed in a research note on Thursday, December 18th. They set an “overweight” rating for the company.

CervoMed Trading Down 0.2%

Shares of CervoMed stock opened at $4.23 on Tuesday. The company has a market cap of $39.17 million, a PE ratio of -1.42 and a beta of -0.77. The company has a 50 day moving average of $5.21 and a 200-day moving average of $7.19. CervoMed has a 1-year low of $3.58 and a 1-year high of $16.94.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings data on Friday, March 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.09). CervoMed had a negative net margin of 672.80% and a negative return on equity of 96.04%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.84 million. Research analysts forecast that CervoMed will post -1.88 earnings per share for the current year.

CervoMed News Roundup

Here are the key news stories impacting CervoMed this week:

• Positive Sentiment: New clinical data presented at the AD/PD 2026 conference show that neflamapimod produced greater benefit in Dementia with Lewy Bodies (DLB) patients who have low plasma pTau181 (i.e., likely without Alzheimer’s co‑pathology). This can increase the perceived commercial and regulatory value of the program for a clearer DLB target population. GlobeNewswire: AD/PD 2026 Data
• Positive Sentiment: HC Wainwright reiterated a Buy and a $25 price target while trimming some near-term EPS forecasts but raising several quarterly and FY2026/FY2027 estimates overall (and raising some quarter estimates). The firm’s maintained Buy and higher longer‑term estimates support upside expectations. MarketBeat: HC Wainwright Notes
• Positive Sentiment: Chardan Capital raised its price target from $15 to $21 and kept a Buy rating, signaling investor conviction from another boutique healthcare analyst. TickerReport: Chardan Raise
• Positive Sentiment: D. Boral Capital published a Buy rating on CRVO, adding to the list of brokers expressing conviction in the story. American Banking News: Buy Rating
• Neutral Sentiment: Coverage notes and press summaries report the company was “flat” on Q4/FY results; no new material guidance or financing announcements were reported in those summaries. Market reaction may therefore hinge on interpretation of pipeline updates and analyst notes. BayStreet: Flat on Q4/FY
• Neutral Sentiment: Reported short‑interest data for March are effectively meaningless in the published entry (shows 0 shares / NaN change), so short‑squeeze or added short pressure is not an active driver based on that report.
• Negative Sentiment: Roth MKM lowered its price target from $19 to $11 (while still on Buy), which reduces near‑term analyst upside and could pressure sentiment among investors focused on published targets. Benzinga: Roth MKM PT Cut
• Negative Sentiment: HC Wainwright trimmed its Q1 2026 EPS estimate (worse near‑term quarterly view), underscoring continued execution and cash‑burn risk until definitive late‑stage data or partnering/financing alleviates funding concerns.

Institutional Investors Weigh In On CervoMed

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC acquired a new position in CervoMed during the 1st quarter worth approximately $227,000. Rhumbline Advisers grew its stake in shares of CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after purchasing an additional 1,526 shares during the last quarter. Marshall Wace LLP acquired a new stake in CervoMed during the 2nd quarter valued at approximately $76,000. Jane Street Group LLC bought a new stake in shares of CervoMed in the 2nd quarter valued at $414,000. Finally, Perigon Wealth Management LLC increased its position in shares of CervoMed by 66.0% during the third quarter. Perigon Wealth Management LLC now owns 28,731 shares of the company’s stock worth $232,000 after buying an additional 11,425 shares during the period. 25.15% of the stock is owned by institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.